FIELD: medicine.
SUBSTANCE: invention relates to method of treating tumour by introduction to subject of c-met antagonist, where lung tumour contains hyperstabilised polypeptide of human c-met with deletion of amino acid part L964 - D1010 of amino acid sequence (given in formula), due to which c-met degradation is reduced in comparison with c-met if wild type. Hyperstabilised polypeptide of c-met binds c-met ligand and possesses c-met activity with respect to signal transmission. In invention it is shown that antagonist is introduced together with substance, inducing degradation of receptor protein. C-met antagonist can represent peptide-antagonist, antibody-c-met antagonist, in particular monovalent antibody, humanised, human or chimeric.
EFFECT: invention makes it possible to inhibit c-met activity with antagonist due to enhancement of cell degradation of hyperstabilised c-met protein either due to inhibition of phosphorolation of hyperstabilised c-met protein or member of cascade of HGF-c-met signal transmission.
10 cl, 1 ex, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTI c-met ANTAGONISTS | 2005 |
|
RU2398777C2 |
| METHODS AND COMPOSITIONS FOR ACTIVATION MODULATION OF HEPATOCYTE GROWTH FACTOR | 2005 |
|
RU2405041C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| METHODS AND COMPOSITIONS FOR HEPSIN MODULATION OF MACROPHAGE-STIMULATING PROTEIN | 2010 |
|
RU2539772C2 |
| COMPOSITIONS AND METHODS FOR DIAGNOSTICS AND TREATMENT OF TUMOUR | 2010 |
|
RU2563359C2 |
| HGF BETA-CHAIN VERSIONS | 2006 |
|
RU2403261C2 |
| ANTI-HEPSIN ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2010 |
|
RU2559533C2 |
| ANTI-BV8 ANTIBODIES AND USING THEM | 2010 |
|
RU2559542C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | 2014 |
|
RU2820869C1 |
